在口腔癌中CD44,p16和VEGF的免疫表达
Priscila Marinho de Abreu1, Marcella Sol2, Patrícia Roccon Bianchi Molini3
1Biotechnology Program, Universidade Federal do Espírito Santo - UFES, Vitória, ES, Brazil.
Journal of oral and maxillofacial pathology : JOMFP
|August 19, 2024
概括
瘤VEGF,p16和CD44不是口腔状细胞癌 (OSCC) 的可靠预后生物标志物. 然而,高层体内VEGF表达可能表明OSCC患者的无病生存率更好.
科学领域:
- 在瘤学瘤学.
- 免疫组织化学 免疫组织化学
- 生物标志物研究 生物标志物研究
背景情况:
- 口腔状细胞癌 (OSCC) 是一个重要的全球健康问题.
- 确定可靠的预后生物标志物对于改善患者的治疗结果至关重要.
- CD44,p16和血管内皮生长因子 (VEGF) 已被研究为各种癌症的潜在生物标志物.
研究的目的:
- 在OSCC中研究CD44,p16和VEGF的免疫表达.
- 为了将这些标记与临床病理学参数和生存率相关联.
- 为了澄清这些生物标志物在OSCC中的预后影响.
主要方法:
- 在68个OSCC样本上进行了免疫组织化学检查.
- 量化了CD44,p16和VEGF的表达水平.
- 统计分析包括奇平方测试,费舍尔精确测试,卡普兰-梅尔法和日志等级测试.
主要成果:
- 在瘤VEGF,p16,CD44表达和临床病理特征之间没有发现显著的相关性.
- 患有高 stromal VEGF 表达的患者表现出明显更好的无疾病生存率 (P=0.023).
结论:
- 瘤VEGF,p16和CD44不是OSCC的有效预后生物标志物.
- 流体VEGF表达显示出作为OSCC的预后生物标志物的潜力.
- 需要进一步的研究来验证体VEGF作为预后指标.
更多相关视频
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
9.6K
07:01Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
10.1K
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.